Regeneron Pharmaceuticals (REGN)

• Market cap: $75.4B
• 1 day: -1.52%
• 5 days: -4.19%
• 1 month: -6.15%
• 3 months: -32.33%
• 6 months: -36.58%
• Year to date: -4.04%
• 1 year: -26.78%
• 5 years: 81.12%
• 10 years: 68.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 14,176

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

99% more first-time investments, than exits

New positions opened: 137 | Existing positions closed: 69

17% more repeat investments, than reductions

Existing positions increased: 529 | Existing positions reduced: 453

4% more funds holding

Funds holding: 1,309 [Q2] → 1,359 (+50) [Q3]

5% less capital invested

Capital invested by funds: $109B [Q2] → $104B (-$5.04B) [Q3]

3.43% less ownership

Funds ownership: 95.63% [Q2] → 92.2% (-3.43%) [Q3]

18% less funds holding in top 10

Funds holding in top 10: 28 [Q2] → 23 (-5) [Q3]

23% less call options, than puts

Call options by funds: $1.45B | Put options by funds: $1.88B

Research analyst outlook

16 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $165 76% downside
• Avg. target: $996 45% upside
• High target: $1,215 77% upside

16 analyst ratings

• positive: 12 75%
• neutral: 3 19%
• negative: 1 6%

Wells Fargo Mohit Bansal 38% 1-year accuracy 10 / 26 met price target	31% upside $900	Overweight Maintained	10 Jan 2025
Truist Securities Srikripa Devarakonda 36% 1-year accuracy 12 / 33 met price target	46% upside $1,004	Buy Maintained	8 Jan 2025
Bernstein William Pickering 43% 1-year accuracy 3 / 7 met price target	56% upside $1,070	Outperform Maintained	7 Jan 2025
Canaccord Genuity John Newman 54% 1-year accuracy 14 / 26 met price target	76% downside $165	Hold Initiated	17 Dec 2024
B of A Securities Tim Anderson 33% 1-year accuracy 2 / 6 met price target	18% downside $565	Underperform Reinstated	10 Dec 2024